NEW YORK (360Dx) – Vermillion reported today a 44 percent rise in first quarter revenues.

For the three months ended March 31, the Austin, Texas-based cancer diagnostics firm said that total revenues rose to $726,000 from $505,000 in the year-ago quarter.

Product revenues were $678,000, up from $505,000 in Q1 2016. Service revenues were $48,000. The company posted no service revenues in the year-ago quarter as it had not yet launched its Aspira IVD service business.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.